Is vasoplegic syndrome more prevalent with open-heart procedures compared with isolated on-pump CABG surgery?

Cardiovascular Revascularization Medicine

Volumn 12, Issue 4, 2011, Pages 203-209

  Sun, Xiumei ^a   Boyce, Steven W ^a   Herr, Daniel L ^a   Hill, Peter C ^a   Zhang, Li ^a   Corso, Paul J ^a   Haile, Elizabeth ^a   Lee, Anne T ^a   Molyneaux, Robert E ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

On pump CABG surgery; Open heart surgery; Postoperative vasoplegic syndrome; Risk factors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; STEROID;

ADULT; AGE; AGED; ANEURYSM SURGERY; AORTA DISSECTION; ARTICLE; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REPAIR; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; ON PUMP CORONARY ARTERY BYPASS GRAFT; OPEN HEART SURGERY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; VASOPLEGIA;

AGED; CORONARY ARTERY BYPASS; CORONARY ARTERY BYPASS, OFF-PUMP; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VASOPLEGIA;

EID: 79960737431     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2010.10.004     Document Type: Article

References (21)

1. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998, 116:973-980.
2. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004, 77:496-499.
3. Carrel T, Englberger L, Mohacsi P, et al. Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg 2000, 15:347-353.
4. Ozal E, Kuralay E, Yildirim V, et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg 2005, 79:1615-1619.
5. Sun X, Zhang L, Hill PC, Lowery R, et al. Is incidence of postoperative vasoplegic syndrome different between off-pump and on-pump coronary artery bypass grafting surgery?. Eur J Cardiothorac Surg 2008, 34:820-825.
6. Weis F, Kilger E, Beiras-Fernandez A, et al. Association between vasopressor dependence and early outcome in patients after cardiac surgery. Anaesthesia 2006, 61:938-942.
7. Tuman KJ, McCarthy RJ, O'Connor CJ, et al. Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass. Anesth Analg 1995, 80:473-479.
8. Mekontso-Dessap A, Houël R, Soustelle C, et al. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 2001, 71:1428-1432.
9. Leyh RG, Kofidis T, Struber M, et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass. J Thorac Cardiovasc Surg 2003, 125:1426-1431.
10. Miller BE, Levy JH The inflammatory response to cardiopulmonary bypass. J Cardiothorac Vasc Surg 1997, 11:355-366.
11. Ascione R, Lloyd CT, Underwood MJ, et al. Inflammatory response after coronary revascularization with or without cardiopulmonary bypass. Ann Thorac Surg 2000, 69:1198-1204.
12. Fromes Y, Gaillard D, Ponzio O, et al. Reduction of the inflammatory response following coronary bypass grafting with total minimal extracorporeal circulation. Eur J Cardio-Thorac Surg 2002, 22:527-533.
13. Levin MA, Lin HM, Castillo JG, et al. Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation 2009, 120:1664-1671.
14. Prondzinsky R, Knüpfer A, Loppnow H, et al. Surgical trauma affects the proinflammatory status after cardiac surgery to a higher degree than cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005, 129:760-766.
15. Beeri R, Yosefy C, Guerrero JL, et al. Early repair of moderate ischemic mitral regurgitation reverses left ventricular remodeling: a functional and molecular study. Circulation 2007, 116(Supp1):I 288-I 293.
16. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Eng J Med 2005, 352:875-883.
17. Schillinger M, Domanovits H, Bayegan K, et al. C-reactive protein and mortality in patients with acute aortic disease. Intensive Care Med 2002, 28:740-745.
18. Licker M, Neidhart P, Lustenberger S, et al. Long-term angiotensin-converting enzyme inhibitor treatment attenuate adrenergic responsiveness without altering hemodynamic control in patients undergoing cardiac surgery. Anesthesiology 1996, 84:789-800.
19. Raja SG, Fida N Should angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists be omitted before cardiac surgery to avoid postoperative vasodilation?. Interact Cardiovasc Thorac Surg 2008, 7:470-475.
20. Papadopoulos G, Sintou E, Siminelakis S, et al. Perioperative infusion of low-dose of vasopressin for prevention and management of vasodilatory vasoplegic syndrome in patients undergoing coronary artery bypass grafting-A double-blind randomized study. J Cardiothoracic Surg 2010, 5:17-23.
21. Gammie JS, Sheng S, Griffith BP, et al. Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Database. AnnThorac Surg 2009, 87:1431-1439.